Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6005902 | 0.82 | ADORA2A (0.48) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5653322 | 0.82 | ADORA2A (0.71) | ADORA2AADORA1ADORA2B | |
| SCHEMBL7152951 | 0.81 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL6047213 | 0.81 | ADORA2A (0.82) | ADORA2A | |
| SCHEMBL12612295 | 0.80 | ADORA2A (0.68) | ADORA2AADORA1ADORA2B | |
| SCHEMBL19596873 | 0.80 | ADORA2A (0.68) | ADORA2A | |
| SCHEMBL3541623 | 0.80 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL6047246 | 0.80 | ADORA2A (0.57) | ADORA2AADORA1ADORA2B | |
| SCHEMBL6047267 | 0.79 | ADORA2A (0.74) | ADORA2A | |
| SCHEMBL3548828 | 0.79 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027075-A1 | SULFONAMIDE COMPOUNDS TARGETING CD73 AND ADENOSINE RECEPTORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-01-26 | — | — | US | claimed |
| EP-1633756-A2 | A2A ADENOSINE RECEPTOR ANTAGONISTS | Biogen Idec MA Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| WO-2004092173-A2 | A2A ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN IDEC MA INC. (US) | 2004-10-28 | — | — | WO | claimed |
| US-20230027075-A1 | SULFONAMIDE COMPOUNDS TARGETING CD73 AND ADENOSINE RECEPTORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-01-26 | — | — | US | disclosed |
| US-7834014-B2 | Parkinson's disease; [2-(7-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)-octahydro-pyrido[1,2-a]pyrazin-7-yl]-methanol; | BIOGEN IDEC MA INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090029967-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS | SCHERING CORPORATION | 2009-01-29 | — | — | US | disclosed |
| US-7470698-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7414058-B2 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | SCHERING CORPORATION (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070249641-A1 | ADENOSINE A3 RECEPTOR MODULATORS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2007-10-25 | — | — | US | disclosed |
| US-7271171-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070173505-A1 | A2a adenosine receptor antagonists | BIOGEN IDEC MA INC. | 2007-07-26 | — | — | US | disclosed |
| US-20040138235-A1 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | SCHERING CORPORATION | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173505-A1 | A2a adenosine receptor antagonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885ADORA2B 4/4885 |
| US-20090029967-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA1 8/4885ADORA2B 3/4885 |
| US-20230027075-A1 | SULFONAMIDE COMPOUNDS TARGETING CD73 AND ADENOSINE RECEPTORS | ADORA2A, ADORA2B, ENTPD5 | ADORA2A 1/4885ADORA1 4/4885ADORA2B 2/4885 |
| US-20070249641-A1 | ADENOSINE A3 RECEPTOR MODULATORS | ADORA3, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885ADORA2B 4/4885 |
| US-20040138235-A1 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA1 8/4885ADORA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.